Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
According to Zacks, “Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden. “
Separately, Deutsche Bank downgraded shares of Swedish Orphan Biovitrum AB (publ) from a “buy” rating to a “hold” rating in a research note on Thursday, July 18th.
Swedish Orphan Biovitrum AB (publ) Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Featured Article: How to invest using market indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.